Bain Capital Public Equity Management II’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bain Capital Public Equity Management II’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-224,763	Closed	-$2.38M	–	39
2022 Q2	$2.38M	Sell	224,763 -295,436	-57%	-$3.05M	0.12%	38
2022 Q1	$8.46M	Sell	520,199 -907,178	-64%	-$14.6M	0.27%	38
2021 Q4	$19.8M	Sell	1,427,377 -45,094	-3%	-$597K	0.66%	32
2021 Q3	$21.2M	Sell	1,472,471 -88,259	-6%	-$1.39M	0.74%	34
2021 Q2	$24.7M	Buy	1,560,730 +842,000	+117%	+$11.4M	1.06%	26
2021 Q1	$7.31M	Buy	+718,730	New	+$7.41M	0.3%	43

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Bain Capital Public Equity Management II's BCRX Position: Q3 2022 in Review

Bain Capital Public Equity Management II sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2022, closing a stake of 224,763 shares — an estimated $2.38M sold.

Bain Capital Public Equity Management II first reported a position in BCRX in Q1 2021 and held it in 6 quarters. The position peaked at $24.7M in Q2 2021. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

Bain Capital Public Equity Management II reported no remaining BioCryst Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Bain Capital Public Equity Management II sold 224,763 BioCryst Pharmaceuticals shares in Q3 2022, an estimated $2.38M.
Bain Capital Public Equity Management II first reported a position in BioCryst Pharmaceuticals in Q1 2021 and held it in 6 quarters.
Bain Capital Public Equity Management II's BioCryst Pharmaceuticals position peaked at $24.7M in Q2 2021.
234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on Bain Capital Public Equity Management II's 13F filing for Q3 2022, filed 14 Nov 2022.